Retina

U.K. Ophthalmologists are the leading adopters of Oraya Therapy for the treatment of wet age-related macular degeneration (AMD), two years after the treatment was introduced in the country.

Anti-VEGF monotherapy may not be adequate for all your wet AMD patients. The Oraya Therapy™ Stereotactic Radiotherapy for Wet AMD, intended as a one-time treatment, has been shown to maintain vision while reducing the number of anti-VEGF injections, providing a viable option for patients with significant fluid in the macula.

Christopher Brand, Consultant Ophthalmic Surgeon, discusses the treatment of recently diagnosed wet AMD patients

Professor Dr. Salvatore Grisanti reviews selection criteria for best outcomes using Oraya Therapy for wet AMD

Dr. med Katja Hatz discusses the treat and extend approach to wet AMD with the Oraya Therapy

Consultant ophthalmic surgeon Professor Tariq Aslam shares clinical insights and patient experiences with the Oraya Therapy for the treatment of wet AMD in the UK

Professor Ian Rennie, Consultant Ophthalmologist and International Expert in Treatments of Ocular Cancers, discusses the safe use of radiotherapy for the treatment of wet AMD

Consultant ophthalmic surgeon Timothy L. Jackson, PhD FRCOphth reviews 3-year safety data of stereotactic radiotherapy for the treatment for wet AMD

Time-elapsed clinical images demonstrating the treatment results and impact of Oraya Therapy on wet AMD

Time-elapsed clinical images demonstrating the treatment results and impact of Oraya Therapy on wet AMD